Skip to main content
Article
Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma.
Journal of Clinical Oncology (2017)
  • Michael B. Atkins, Georgetown University
  • Ragini Reiney Kudchadkar, Emory University
  • Mario Sznol, Yale Cancer Center
  • David F. McDermott, Harvard University
  • Michal Lotem, National Institutes of Health
  • Jacob Schachter, Sheba Medical Center
  • Jedd D. Wolchok, Memorial Sloan Kettering Cancer Center
  • Walter John Urba
  • Timothy Kuzel, Rush University Medical Center
  • Lynn Mara Schuchter, University of Pennsylvania
  • Craig L. Slingluff, University of Virginia
  • Marc S. Ernstoff, Dartmouth College
  • Joseph W. Fay, Baylor University
  • Philip Adam Friedlander, Icahn School of Medicine at Mount Sinai
  • Thomas Gajewski, University of Chicago
  • Hassane M. Zarour, University of Pittsburgh
  • Rinat Rotem-Yehudar
  • Jeffrey Alan Sosman, Vanderbilt University
Publication Date
January 31, 2017
Citation Information
Michael B. Atkins, Ragini Reiney Kudchadkar, Mario Sznol, David F. McDermott, et al.. "Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma." Journal of Clinical Oncology (2017)
Available at: http://works.bepress.com/walter-urba/100/